Bayer and Evotec Focus on Advancing Precision Cardiology

Bayer and Evotec announced a strategic shift in their collaboration towards developing precision treatments for cardiovascular diseases (CVDs). The partnership will exploit Evotec's disease modelling capabilities using human induced pluripotent stem cells (iPSCs) to identify novel targets for therapy development.

Officials from both companies emphasized the need for innovation in the field of cardiology. They highlighted that cardiovascular diseases remain the leading cause of global mortality and this collaboration focuses on addressing areas of significant unmet medical needs by developing disease-modifying therapies.

Under the agreement, both Bayer and Evotec will share pre-clinical development responsibilities for potential clinical candidates, while Bayer will handle further clinical development and commercialization. Financial terms of the deal were not disclosed.